Previous 10 | Next 10 |
home / stock / enscw / enscw news
~ PF614-MPAR will be the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / December 19, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve pr...
SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricin...
~ Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech ...
Corporate Update Call to be Held Wednesday, November 16, 2022 SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescrip...
~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~ SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transfor...
~ Announces Timing of Corporate Update Call ~ SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focus...
~ Critical Study to Support Abuse Deterrent Labeling ~ SAN DIEGO, CA / ACCESSWIRE / October 28, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug ...
San Diego, California--(Newsfile Corp. - October 12, 2022) - Ensysce Biosciences, Inc. (NASDAQ: ENSC) (OTC Pink: ENSCW) ("Ensysce" or the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today annou...
~ Oral Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~ SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:...
SAN DIEGO, CA / ACCESSWIRE / September 21, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that ...
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc Warrants (05/12/2019) Company Name:
ENSCW Stock Symbol:
OTCMKTS Market:
Ensysce Biosciences Inc Warrants (05/12/2019) Website:
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...
~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions ...
~ Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder ~ SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions...